- Home
- FOA vs LYEL Comparison
FOA vs LYEL Comparison
Compare FOA & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- LYEL
- Stock Information
- Founded
- FOA 2013
- LYEL 2018
- Country
- FOA United States
- LYEL United States
- Employees
- FOA N/A
- LYEL N/A
- Industry
- FOA Finance Companies
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- LYEL Health Care
- Exchange
- FOA Nasdaq
- LYEL Nasdaq
- Market Cap
- FOA 272.8M
- LYEL 253.2M
- IPO Year
- FOA N/A
- LYEL 2021
- Fundamental
- Price
- FOA $21.50
- LYEL $16.59
- Analyst Decision
- FOA Buy
- LYEL Hold
- Analyst Count
- FOA 2
- LYEL 3
- Target Price
- FOA $27.50
- LYEL $16.67
- AVG Volume (30 Days)
- FOA 119.3K
- LYEL 31.2K
- Earning Date
- FOA 11-04-2025
- LYEL 11-12-2025
- Dividend Yield
- FOA N/A
- LYEL N/A
- EPS Growth
- FOA N/A
- LYEL N/A
- EPS
- FOA 7.10
- LYEL N/A
- Revenue
- FOA $527,520,999.00
- LYEL $60,000.00
- Revenue This Year
- FOA $21.21
- LYEL N/A
- Revenue Next Year
- FOA $10.95
- LYEL N/A
- P/E Ratio
- FOA $3.06
- LYEL N/A
- Revenue Growth
- FOA 46.94
- LYEL 11.11
- 52 Week Low
- FOA $11.33
- LYEL $7.65
- 52 Week High
- FOA $32.40
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- FOA 38.78
- LYEL 52.27
- Support Level
- FOA $22.38
- LYEL $16.00
- Resistance Level
- FOA $23.03
- LYEL $18.60
- Average True Range (ATR)
- FOA 0.74
- LYEL 1.13
- MACD
- FOA 0.09
- LYEL -0.25
- Stochastic Oscillator
- FOA 16.19
- LYEL 24.20
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.